| 000185 (2020) |
Shu-Ren Li ; Zi-Jian Tang [République populaire de Chine] ; Zai-Han Li ; Xuan Liu [République populaire de Chine] | Searching therapeutic strategy of new coronavirus pneumonia from angiotensin-converting enzyme 2: the target of COVID-19 and SARS-CoV |
| 000740 (2020) |
Chandramohan Kiruthiga [Inde] ; Kasi Pandima Devi [Inde] ; Seyed Mohammad Nabavi [Iran] ; Anupam Bishayee [États-Unis] | Autophagy: A Potential Therapeutic Target of Polyphenols in Hepatocellular Carcinoma. |
| 000761 (2020) |
Haibo Zhang [République populaire de Chine, Canada] ; Josef M. Penninger [Autriche] ; Yimin Li [République populaire de Chine] ; Nanshan Zhong [République populaire de Chine] ; Arthur S. Slutsky [Canada, République populaire de Chine] | Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target |
| 000307 (2020) |
Milka Mileva [Bulgarie] ; Adriana Dimitrova [Bulgarie] ; Dimo Krastev [Bulgarie] ; Albena Alexandrova [Bulgarie] ; Elina Tsvetanova [Bulgarie] ; Almira Georgieva [Bulgarie] ; Angel Galabov [Bulgarie] | Oseltamivir and S-Adenosyl-L-Methionine Combination as Effective Therapeutic Strategy for Suppression of Oxidative Damage in Lung Caused by Influenza Virus Infection in Mice. |
| 000571 (2020) |
Jiancheng Zhang [Japon, République populaire de Chine] ; Bing Xie [République populaire de Chine] ; Kenji Hashimoto [Japon] | Current status of potential therapeutic candidates for the COVID-19 crisis |
| 000583 (2020) |
Khadga Raj ; Anirban Ghosh ; Shamsher Singh | Coronavirus as silent killer: recent advancement to pathogenesis, therapeutic strategy and future perspectives |
| 000040 (2020) |
Y-X Wang [République populaire de Chine] ; J-R Ma ; S-Q Wang ; Y-Q Zeng ; C-Y Zhou ; Y-H Ru ; L. Zhang ; Z-G Lu ; M-H Wu ; H. Li | Utilizing integrating network pharmacological approaches to investigate the potential mechanism of Ma Xing Shi Gan Decoction in treating COVID-19. |
| 000044 (2020) |
Walter Gottlieb Land [France, Allemagne] | Use of DAMPs and SAMPs as Therapeutic Targets or Therapeutics: A Note of Caution |
| 000071 (2020) |
Lei Li [République populaire de Chine] ; Ranran Li [République populaire de Chine] ; Zhixiong Wu [République populaire de Chine] ; Xianghong Yang ; Mingyan Zhao [République populaire de Chine] ; Jiao Liu [République populaire de Chine] ; Dechang Chen [République populaire de Chine] | Therapeutic strategies for critically ill patients with COVID-19 |
| 000072 (2020) |
Laura Isobel Paddon | Therapeutic or detrimental mobilities? Walking groups for older adults |
| 000080 (2020) |
Chiara Mozzini ; Domenico Girelli | The role of Neutrophil Extracellular Traps in Covid-19: Only an hypothesis or a potential new field of research? |
| 000084 (2020) |
José Alberto Chore O-Parra [Mexique, États-Unis] ; Shyamala Thirunavukkarasu [États-Unis] ; Joaquín Zú Iga [Mexique] ; Shabaana A. Khader [États-Unis] | The protective and pathogenic roles of CXCL17 in human health and disease: Potential in respiratory medicine |
| 000085 (2020) |
Akiko Iwasaki [États-Unis] ; Yexin Yang [États-Unis] | The potential danger of suboptimal antibody responses in COVID-19 |
| 000092 (2020) |
Kenneth Maiese [États-Unis] | The mechanistic target of rapamycin (mTOR): Novel Considerations as an Antiviral Treatment and Possibilities for COVID-19. |
| 000165 (2020) |
Jia Wang ; Zhifeng Wang | Strengths, Weaknesses, Opportunities and Threats (SWOT) Analysis of China’s Prevention and Control Strategy for the COVID-19 Epidemic |
| 000205 (2020) |
Rajvikram Madurai Elavarasan [Inde] ; Rishi Pugazhendhi [Inde] | Restructured society and environment: A review on potential technological strategies to control the COVID-19 pandemic |
| 000213 (2020) |
Mahsa Shabani ; Tom Goffin ; Heidi Mertes | Reporting, Recording and Communication of COVID-19 Cases in Workplace: Data Protection as a Moving Target |
| 000227 (2020) |
Jun Shigemura [Japon] ; Robert J. Ursano [États-Unis] ; Joshua C. Morganstein [États-Unis] ; Mie Kurosawa [Japon] ; David M. Benedek [États-Unis] | Public responses to the novel 2019 coronavirus (2019-nCoV) in Japan: Mental health consequences and target populations. |
| 000231 (2020) |
Wenzhi Wu [République populaire de Chine] ; Yan Zhang [République populaire de Chine] ; Pu Wang [République populaire de Chine] ; Li Zhang [République populaire de Chine] ; Guixiang Wang [République populaire de Chine] ; Guanghui Lei ; Qiang Xiao ; Xiaochen Cao [République populaire de Chine] ; Yueran Bian [République populaire de Chine] ; Simiao Xie [République populaire de Chine] ; Fei Huang [République populaire de Chine] ; Na Luo [République populaire de Chine] ; Jingyuan Zhang [République populaire de Chine] ; Mingyan Luo [République populaire de Chine] | Psychological stress of medical staffs during outbreak of COVID-19 and adjustment strategy. |
| 000250 (2020) |
Jiahuang Qiu [République populaire de Chine] ; Juan Ma [République populaire de Chine] ; Shuping Zhang [République populaire de Chine] ; Jinxiang Han ; Sijin Liu [République populaire de Chine] | Promoting platelets is a therapeutic option to combat severe viral infection of the lung |
| 000255 (2020) |
Suehiro Sakaguchi [Japon] ; Junji Chida [Japon] | Prion Protein is a Novel Modulator of Influenza: Potential Implications for Anti-Influenza Therapeutics. |
| 000276 (2020) |
Rong Li [République populaire de Chine] ; Tailang Yin [République populaire de Chine] ; Fang Fang [République populaire de Chine] ; Qin Li [République populaire de Chine] ; Jiao Chen [République populaire de Chine] ; Yixin Wang [États-Unis] ; Yongxiu Hao [République populaire de Chine] ; Gengxiang Wu [République populaire de Chine] ; Peng Duan [République populaire de Chine] ; Yuanyuan Wang [République populaire de Chine] ; Dan Cheng [République populaire de Chine] ; Qi Zhou [République populaire de Chine] ; Mohammad Ishraq Zafar [République populaire de Chine] ; Chengliang Xiong [République populaire de Chine] ; Honggang Li [République populaire de Chine] ; Jing Yang [République populaire de Chine] ; Jie Qiao [République populaire de Chine] | Potential risks of SARS-Cov-2 infection on reproductive health |
| 000277 (2020) |
Lei Zhang ; Yunhui Liu | Potential interventions for novel coronavirus in China: A systematic review |
| 000278 (2020) |
Zhong Sun ; Karuppiah Thilakavathy ; S. Suresh Kumar [Malaisie] ; Guozhong He [République populaire de Chine] ; Shi V. Liu [États-Unis] | Potential Factors Influencing Repeated SARS Outbreaks in China |
| 000301 (2020) |
Nádia Nara Rolim Lima [Brésil] ; Ricardo Inácio De Souza [Brésil] ; Pedro Walisson Gomes Feitosa [Brésil] ; Jorge Lucas De Sousa Moreira [Brésil] ; Claudio Gleidiston Lima Da Silva [Brésil] ; Modesto Leite Rolim Neto [Brésil] | PEOPLE EXPERIENCING HOMELESSNESS: THEIR POTENTIAL EXPOSURE TO COVID-19 |
| 000303 (2020) |
Amélie Soumier ; Angela Sirigu | Oxytocin as a potential defence against Covid- 19? |
| 000314 (2020) |
Samad Ghaffari [Iran] ; Neda Roshanravan [Iran] ; Helda Tutunchi [Iran] ; Alireza Ostadrahimi [Iran] ; Mahboub Pouraghaei [Iran] ; Behnam Kafil [Iran] | Oleoylethanolamide, A Bioactive Lipid Amide, as A Promising Treatment Strategy for Coronavirus/COVID-19 |
| 000339 (2020) |
Janice S. Mani [Australie] ; Joel B. Johnson [Australie] ; Jason C. Steel [Australie] ; Daniel A. Broszczak [Australie] ; Paul M. Neilsen [Australie] ; Kerry B. Walsh [Australie] ; Mani Naiker [Australie] | Natural product-derived phytochemicals as potential agents against coronaviruses: a review |
| 000373 (2020) |
Casey Means | Mechanisms of increased morbidity and mortality of SARS-CoV-2 infection in individuals with diabetes: what this means for an effective management strategy |
| 000432 (2020) |
Krešimir Osi [Croatie] ; Siniša Popovi ; Marko Šarlija ; Ivan Kesedži | Impact of Human Disasters and COVID-19 Pandemic on Mental Health: Potential of Digital Psychiatry. |
| 000438 (2020) |
Marina Macchiagodena ; Marco Pagliai ; Piero Procacci | Identification of potential binders of the main protease 3CLpro of the COVID-19 via structure-based ligand design and molecular modeling |
| 000562 (2020) |
Wei Liu [République populaire de Chine] ; Shuping Zhang [République populaire de Chine] ; Sergei Nekhai [États-Unis] ; Sijin Liu [République populaire de Chine] | Depriving Iron Supply to the Virus Represents a Promising Adjuvant Therapeutic Against Viral Survival |
| 000611 (2020) |
Emilio A. Herrera ; Alejandro Gonzalez-Candia | Comment on Melatonin as a potential adjuvant treatment for COVID-19 |
| 000661 (2020) |
Rui Zhang [République populaire de Chine] ; Xuebin Wang [République populaire de Chine] ; Leng Ni [République populaire de Chine] ; Xiao Di [République populaire de Chine] ; Baitao Ma [République populaire de Chine] ; Shuai Niu [République populaire de Chine] ; Changwei Liu [République populaire de Chine] ; Russel J. Reiter [États-Unis] | COVID-19: Melatonin as a potential adjuvant treatment |
| 000748 (2020) |
Emily A. Troyer [États-Unis] ; Jordan N. Kohn [États-Unis] ; Suzi Hong [États-Unis] | Are we facing a crashing wave of neuropsychiatric sequelae of COVID-19? Neuropsychiatric symptoms and potential immunologic mechanisms☆ |
| 000756 (2020) |
Elena V. Proskurnina [Russie] ; Dmitry Yu Izmailov [Russie] ; Madina M. Sozarukova [Russie] ; Tatiana A. Zhuravleva [Russie] ; Irina A. Leneva [Russie] ; Artem A. Poromov [Russie] | Antioxidant Potential of Antiviral Drug Umifenovir. |
| 000798 (2020) |
George D. Vavougios [Grèce] | A data-driven hypothesis on the epigenetic dysregulation of host metabolism by SARS coronaviral infection: potential implications for the SARS-CoV-2 modus operandi |
| 000853 (????) |
Mehrdad Zeinalian [Iran] ; Azhar Salari-Jazi [Iran] ; Amin Jannesari [Iran] ; Hossein Khanahmad [Iran] | A potential protective role of losartan against coronavirus-induced lung damage |
